Abstract
Lung cancers are the leading cause of cancer-related deaths worldwide. Studies have shown that non-small cell lung cancer (NSCLC) which constitutes majority of lung cancers, are significantly more responsive to early-stage interventions. However, the early stages are often asymptomatic, and current diagnostic methods are limited in their precision and safety. The cell-free RNAs (cfRNA) circulating in plasma (Liquid biopsies) offer non-invasive detection of spatial and temporal changes occurring in primary tumors since early stages. To address gaps in current cfRNA knowledgebase, we conducted a pilot study for comprehensive analysis of transcriptome-wide changes in plasma cfRNA in NSCLC patients. Total cfRNA was extracted from archived plasma collected from NSCLC patients (N=12), cancer-free former smokers (N=12) and non-smoking healthy volunteers (N=12). Plasma cfRNA expression levels were quantified by using a tagmentation-based library preparation and sequencing. The comparisons of cfRNA expression levels between patients and the two control groups revealed a total of 2357 differentially expressed cfRNA enriched in 123 pathways. Of these, 251 transcripts were previously reported in primary NSCLCs. A small subset of genes (N=5) was validated in an independent sample (N=50) using qRT-PCR. Our study provides a framework for developing blood-based assays for early detection of NSCLC and warrants further validation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by NCI-U24CA11509-01 (SS), FDA-5U01FD005946-06(FJ), and NCI-UH2CA229132 (FJ).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of the University of Maryland Baltimore [UMB IRB protocol ID: HP-00040666] and the Veterans Affairs Maryland Health Care System [protocol ID: VA-00040666].
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
csenevi{at}som.umaryland.edu; JCornell{at}som.umaryland.edu
AShetty{at}som.umaryland.edu; csenevi{at}som.umaryland.edu; cmccracken{at}som.umaryland.edu
kmullins{at}som.umaryland.edu; FJiang{at}som.umaryland.edu; SStass{at}som.umaryland.edu
kmullins{at}som.umaryland.edu; SStass{at}som.umaryland.edu
this includes new data and extensive revisions to all sections.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
